FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M

KYNTRA BIO, INC.

2024-Q1 EPS reported -$0.33 revenue$55,902,000

Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.
Roxadustat China net sales by FibroGen and JDE totaled $79.4M, up 24% YoY on 39% volume growth.
Topline data for pamrevlumab in metastatic pancreatic cancer expected mid-2024; LAPIS Phase 3 data in 3Q 2024.
Phase 1 FG-3246 (CD46 ADC) in mCRPC showed median rPFS of 8.7 months; 20% partial response rate.
Cash and receivables $214.7M; runway into 2026; FY 2024 roxadustat revenue guidance reaffirmed $120-135M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.